Breadcrumb

[A18-40] Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)

Overview

Overview

Commission: Commission awarded on 2018-06-15 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Drug Assessment
Current document:PDF Executive summary of dossier assessment  [PDF, 85 kB] (German version) Further documents
Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Contact address:to the contact form
Linked projects: [G17-10] Nivolumab Squamous cell carcinoma of the head and neck - Addendum to A17-24
Status: Commission completed

[A19-11] Nivolumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed

[A18-53] Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed

[A17-54] Nivolumab (squamous cell carcinoma of the head and neck) - Addendum to Commission A17-24
Status: Commission completed

[A17-29] Nivolumab (urothelial carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed

[A17-27] Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Status: Commission completed

[A17-24] Nivolumab (squamous cell carcinoma of the head and neck) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed

[A17-21] Nivolumab (classical Hodgkin lymphoma) - Addendum to Commission A16-76
Status: Commission completed

[A16-76] Nivolumab (Hodgkin lymphoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed

[A16-68] Nivolumab (melanoma) - Addendum to Commission A16-35
Status: Commission completed

[A16-57] Nivolumab (NSCLC) - Addendum to Commission A16-25
Status: Commission completed

[A16-56] Nivolumab (renal cell carcinoma) - Addendum to Commission A16-24
Status: Commission completed

[A16-35] Nivolumab (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed

[A16-25] Nivolumab (new therapeutic indication) – Benefit assessment according to §35a SGB V
Status: Commission completed

[A16-24] Nivolumab (new therapeutic indication) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed

[A15-58] Nivolumab - Addendum to Commission A15-32
Status: Commission completed

[A15-50] Nivolumab - Addendum to Commission A15-27
Status: Commission completed

[A15-32] Nivolumab (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment)
Status: Commission completed

[A15-27] Nivolumab – Benefit assessment according to §35a Social Code Book V (dossier assessment)
Status: Commission completed


Report documents

Report documents

PublishedDocumentSizeType 
2018-09-17 Executive summary of dossier assessment (German version) 85 kBPDFdownload file
2018-09-17 Dossier assessment (German version) 3 MBPDFdownload file

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.



Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close